Taho Pharmaceuticals Ltd. (TPEX:6467)
Taiwan · Delayed Price · Currency is TWD 196.00
+2.00 (1.03%)
At close: Sep 19, 2025
Taho Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2017 | FY 2016 | 2011 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | 2011 - 2015 |
Operating Revenue | 7.78 | - | 1.07 | 6.36 | 12.4 | 36.01 | Upgrade |
| 7.78 | - | 1.07 | 6.36 | 12.4 | 36.01 | Upgrade | |
Revenue Growth (YoY) | - | - | -83.23% | -48.73% | -65.56% | 2.68% | Upgrade |
Cost of Revenue | 2.9 | - | 1.14 | 1.3 | 13.54 | 22.36 | Upgrade |
Gross Profit | 4.88 | - | -0.07 | 5.06 | -1.14 | 13.65 | Upgrade |
Selling, General & Admin | 25.49 | 23.97 | 17.36 | 15.17 | 34.85 | 58.12 | Upgrade |
Research & Development | 150.87 | 146.16 | 106.44 | 55.21 | 71.27 | 64.33 | Upgrade |
Operating Expenses | 176.37 | 170.13 | 121.03 | 71.76 | 106.12 | 122.45 | Upgrade |
Operating Income | -171.49 | -170.13 | -121.1 | -66.71 | -107.25 | -108.8 | Upgrade |
Interest Expense | -0.8 | -0.9 | -1.39 | -0.53 | -0.03 | -0 | Upgrade |
Interest & Investment Income | 5.06 | 3.02 | 1.3 | 0.52 | 0.63 | 0.31 | Upgrade |
Currency Exchange Gain (Loss) | 0.86 | 0.34 | 0.27 | - | -6.55 | -2.15 | Upgrade |
Other Non Operating Income (Expenses) | 0.42 | 0.24 | 0.24 | 0.43 | -18.16 | 1.46 | Upgrade |
EBT Excluding Unusual Items | -165.97 | -167.44 | -120.68 | -66.3 | -131.36 | -109.19 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | -5.78 | - | Upgrade |
Pretax Income | -165.97 | -167.44 | -120.68 | -66.3 | -137.14 | -109.19 | Upgrade |
Net Income | -165.97 | -167.44 | -120.68 | -66.3 | -137.14 | -109.19 | Upgrade |
Net Income to Common | -165.97 | -167.44 | -120.68 | -66.3 | -137.14 | -109.19 | Upgrade |
Shares Outstanding (Basic) | 49 | 45 | 39 | 36 | 52 | 52 | Upgrade |
Shares Outstanding (Diluted) | 49 | 45 | 39 | 36 | 52 | 52 | Upgrade |
Shares Change (YoY) | 17.82% | 17.18% | 7.73% | -31.26% | - | - | Upgrade |
EPS (Basic) | -3.37 | -3.69 | -3.12 | -1.84 | -2.62 | -2.09 | Upgrade |
EPS (Diluted) | -3.37 | -3.69 | -3.12 | -1.84 | -2.62 | -2.09 | Upgrade |
Free Cash Flow | -171.97 | -165.73 | -107.1 | -63.61 | -138.44 | -103.23 | Upgrade |
Free Cash Flow Per Share | -3.49 | -3.65 | -2.76 | -1.77 | -2.65 | -1.97 | Upgrade |
Gross Margin | 62.67% | - | -6.75% | 79.52% | -9.16% | 37.90% | Upgrade |
Operating Margin | -2204.54% | - | -11359.94% | -1049.20% | -864.87% | -302.11% | Upgrade |
Profit Margin | -2133.50% | - | -11321.11% | -1042.75% | -1105.89% | -303.19% | Upgrade |
Free Cash Flow Margin | -2210.67% | - | -10047.00% | -1000.49% | -1116.35% | -286.63% | Upgrade |
EBITDA | -168.68 | -168.32 | -118.54 | -57.77 | -91.5 | -92.86 | Upgrade |
EBITDA Margin | - | - | - | - | - | -257.84% | Upgrade |
D&A For EBITDA | 2.81 | 1.81 | 2.56 | 8.94 | 15.76 | 15.94 | Upgrade |
EBIT | -171.49 | -170.13 | -121.1 | -66.71 | -107.25 | -108.8 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.